Infinity Pharmaceuticals, Inc. INFIQ
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 15.88% | 30.79% | 39.56% | 35.70% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.88% | 30.79% | 39.56% | 35.70% | -- |
| Cost of Revenue | -17.30% | -8.26% | 3.68% | 12.22% | -- |
| Gross Profit | 19.57% | 10.79% | -1.53% | -10.76% | -- |
| SG&A Expenses | 11.97% | 10.13% | -5.02% | -1.44% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.75% | -2.78% | 1.06% | 7.99% | -- |
| Operating Income | 9.92% | 4.28% | 0.53% | -6.82% | -- |
| Income Before Tax | 12.48% | 6.71% | 1.97% | -5.84% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 12.48% | 6.71% | 1.97% | -5.84% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 12.48% | 6.71% | 1.97% | -5.84% | -- |
| EBIT | 9.92% | 4.28% | 0.53% | -6.82% | -- |
| EBITDA | 9.90% | 4.24% | 0.49% | -6.92% | -- |
| EPS Basic | 12.92% | 7.14% | 6.60% | 7.43% | -- |
| Normalized Basic EPS | 12.92% | 7.11% | 6.56% | 7.43% | -- |
| EPS Diluted | 12.59% | 7.33% | 6.79% | 8.22% | -- |
| Normalized Diluted EPS | 12.92% | 7.11% | 6.56% | 7.43% | -- |
| Average Basic Shares Outstanding | 0.53% | 0.46% | 4.33% | 12.46% | -- |
| Average Diluted Shares Outstanding | 0.53% | 0.46% | 4.33% | 12.46% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |